STAT Washington correspondent Rachel Cohrs joins us to explain how PhRMA, the all-powerful lobbying group, lost its edge in a fight over drug-pricing negotiation. Damian gives us the inside scoop on CTAD, the big Alzheimer's disease research conference, where Eisai and Biogen presented groundbreaking data on their treatment called lecanemab. We also discuss the FDA approval of a microbiome drug for the treatment of a bowel disorder and the potential for a big acquisition of Horizon Therapeutics.

236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Business

Investing

Careers

Management & Marketing

Business News

Shopping

We preview some of the research that will be presented at The American Society of Clinical Oncology conference in Chicago. We also discuss the latest news in the health and life sciences, including a milestone in lung disease R&D and a Duchenne muscular dystrophy confirmatory trial failure.  
To read more about Merus' combination therapy, go here; For more on Johnson & Johnson's mixed data, click here; For more on Nippon Shinyaku's Duchenne drug trial failure, go here; To read more on Insmed's bronchiectasis treatment, click here; To sign up for STAT's ASCO newsletter, click here.

308: An ASCO preview & another Duchenne trial failure

This week on “The Readout LOUD,” STAT's Chief Washington Correspondent Rachel Cohrs Zhang joins us to discuss the layoffs at trade group BIO and how things may be changing at the trade group. We also invite STAT reporter Eric Boodman on to talk about his new investigative series of stories exploring how Black women with sickle cell disease were coerced into getting sterilized.

307: More tumult at BIO & coercive care for sickle cell patients

On this week’s "Readout LOUD," we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on that note, we chat with our AI correspondent — and recent Pulitzer finalist — Casey Ross, who sat down on stage to discuss AI-centered drug discovery with both NVIDIA and Google-backed Isomorphic Labs.
We also discuss this week’s biotech news, including yet more obesity drug data, this time from Roche, and the closing of Novartis’ acquisition of MorphoSys.

306: Live! From the STAT Breakthrough Summit West

This week on "The Readout LOUD," STAT senior infectious diseases reporter Helen Branswell walks us through ongoing H5N1 outbreak in the U.S. and issues with monitoring the spread. And in a bit of shameless self-promotion, we’ll talk to our colleagues Bob Herman and Casey Ross about being named Pulitzer finalists in investigative reporting for their reporting on United Healthcare’s use of algorithms in coverage decisions. We'll hear what’s happened since their explosive work was published last year.

305: Everything you need to know about H5N1 bird flu

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation. We also discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting team.

236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval

Download our free app to listen on your phone